← back to search

Rohit Jain

Gujarat Cancer Society · IN
Area of research
Surgery · Oncology
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies, and Renal cell carcinoma treatment.
h-index
42
citations
8,993
works
280
NIH funding
primary concept
Medicine
email

Recent publications

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Annals of Oncology 2024cited by 81position: middledoi
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy
Journal of Clinical Oncology 2024cited by 23position: middledoi
Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease
Nature Reviews Urology 2023cited by 53position: middledoi
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma
JAMA Oncology 2022cited by 139position: middledoi
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma
Cancer Immunology Immunotherapy 2022cited by 13position: middledoi
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Journal of Clinical Oncology 2021cited by 525position: middledoi
Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption
Cell 2021cited by 401position: middledoi
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
European Urology 2021cited by 82position: middledoi
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.
Journal of Clinical Oncology 2021cited by 42position: middledoi
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
British Journal of Urology 2021cited by 30position: middledoi
Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
Clinical Genitourinary Cancer 2020cited by 105position: middledoi
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
The Lancet Oncology 2019cited by 173position: middledoi
Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen
Immunity 2018cited by 387position: middledoi
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis
Science Translational Medicine 2017cited by 266position: middledoi
ILC2s and T cells cooperate to ensure maintenance of M2 macrophages for lung immunity against hookworms
Nature Communications 2015cited by 155position: middledoi
Granzyme B Promotes Cytotoxic Lymphocyte Transmigration via Basement Membrane Remodeling
Immunity 2014cited by 130position: middledoi
The Skin Immune Atlas: Three-Dimensional Analysis of Cutaneous Leukocyte Subsets by Multiphoton Microscopy
Journal of Investigative Dermatology 2014cited by 123position: middledoi
Real-Time Imaging Reveals the Dynamics of Leukocyte Behaviour during Experimental Cerebral Malaria Pathogenesis
PLoS Pathogens 2014cited by 72position: middledoi
Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells
Nature Immunology 2013cited by 479position: middledoi
Perivascular macrophages mediate neutrophil recruitment during bacterial skin infection
Nature Immunology 2013cited by 290position: middledoi
Intravital multiphoton imaging of immune responses in the mouse ear skin
Nature Protocols 2012cited by 178position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wolfgang Weninger · Centenary Institute7 papers (2012–2015)Petros Grivas · Second Foundation (United States)5 papers (2021–2024)Ben Roediger · Novartis (Switzerland)5 papers (2012–2015)Yohann Loriot · Institut Gustave Roussy3 papers (2021–2024)Richard J. Lee · Center for Cancer Research3 papers (2021–2022)Andrew J. Mitchell · The University of Melbourne3 papers (2013–2014)Daniel P. Petrylak · Yale Cancer Center3 papers (2021–2024)Guru Sonpavde · AdventHealth Orlando3 papers (2021–2023)Philip L. Tong · University of Sydney3 papers (2013–2014)Bradley A. McGregor · Harvard University3 papers (2021–2022)Arjun Vasant Balar · NYU Langone Health3 papers (2021–2024)Phillip L. Palmbos · Cancer Clinic3 papers (2021–2024)Nancy B. Davis · Merck & Co., Inc., Rahway, NJ, USA (United States)3 papers (2021–2024)Neeraj Agarwal · University of Utah3 papers (2021–2024)Cora N. Sternberg · Cornell University3 papers (2021–2024)Scott T. Tagawa · Cornell University3 papers (2021–2024)Arash Rezazadeh Kalebasty · University of California, Irvine3 papers (2021–2024)Manojkumar Bupathi · Rocky Mountain Cancer Centers3 papers (2021–2024)Philippe Beuzeboc · Université Paris Sciences et Lettres2 papers (2021–2024)Philippe Barthélémy · Inserm2 papers (2021–2024)